Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Gains from Sales and Divestitures (2018 - 2024)

Solid Biosciences' Gains from Sales and Divestitures history spans 6 years, with the latest figure at $237315.0 for Q3 2024.

  • For Q3 2024, Gains from Sales and Divestitures changed N/A year-over-year to $237315.0; the TTM value through Sep 2024 reached $237315.0, changed N/A, while the annual FY2023 figure was $183951.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q3 2024 was $237315.0 at Solid Biosciences, up from $230536.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $419193.0 in Q4 2021 and bottomed at $183951.0 in Q4 2023.
  • The 4-year median for Gains from Sales and Divestitures is $237315.0 (2024), against an average of $295739.0.
  • The largest annual shift saw Gains from Sales and Divestitures rose 20.55% in 2020 before it grew 2.82% in 2021.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $407700.0 in 2020, then grew by 2.82% to $419193.0 in 2021, then crashed by 56.12% to $183951.0 in 2023, then grew by 29.01% to $237315.0 in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Gains from Sales and Divestitures are $237315.0 (Q3 2024), $230536.0 (Q2 2024), and $183951.0 (Q4 2023).